byiShook Opinion
Dec 17, 2024 - 12:25
Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 study. The post Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug appeared first on Investor's Business Daily.
Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 study.
The post Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug appeared first on Investor's Business Daily.